Swedbank AB Buys Shares of 55,100 Olema Pharmaceuticals, Inc. $OLMA

Swedbank AB bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 55,100 shares of the company’s stock, valued at approximately $1,378,000. Swedbank AB owned approximately 0.08% of Olema Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Torren Management LLC purchased a new position in Olema Pharmaceuticals during the 4th quarter valued at about $44,000. Russell Investments Group Ltd. purchased a new position in Olema Pharmaceuticals during the 3rd quarter valued at about $53,000. American Century Companies Inc. purchased a new position in Olema Pharmaceuticals during the 2nd quarter valued at about $54,000. Creative Planning purchased a new position in Olema Pharmaceuticals during the 2nd quarter valued at about $83,000. Finally, Nisa Investment Advisors LLC grew its holdings in Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after buying an additional 477 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

Shares of OLMA opened at $14.90 on Monday. The firm has a market cap of $1.30 billion, a P/E ratio of -8.01 and a beta of 2.05. The stock has a 50 day simple moving average of $16.58 and a two-hundred day simple moving average of $20.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.95 and a quick ratio of 9.95. Olema Pharmaceuticals, Inc. has a 1 year low of $3.89 and a 1 year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.01. On average, analysts forecast that Olema Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on OLMA shares. Jefferies Financial Group initiated coverage on Olema Pharmaceuticals in a report on Thursday, March 19th. They set a “buy” rating and a $40.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. upped their price objective on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th. Oppenheimer restated an “outperform” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Finally, The Goldman Sachs Group decreased their price objective on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Olema Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $44.40.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, insider Shawnte Mitchell sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total value of $606,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.56% of the company’s stock.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.